MEDICAL ONCOLOGY Clinical value of circulating tumor cells in breast cancer

Stefan Sleijfer; John Foekens

doi:10.1038/nrclinonc.2011.167

MEDICAL ONCOLOGY Clinical value of circulating tumor cells in breast cancer

Stefan Sleijfer, John Foekens

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Abstract

In a trial in patients with metastatic breast cancer, the prognostic value of the number of circulating tumor cells (CTCs) at baseline was independent of tumor subtype, except in patients with HER2-positive disease treated with anti-HER2 targeted therapy. These data support the use of CTC detection as a tool contributing to personalized medicine.

Original language	Undefined/Unknown
Pages (from-to)	696-698
Number of pages	3
Journal	Nature Reviews Clinical Oncology
Volume	8
Issue number	12
DOIs	https://doi.org/10.1038/nrclinonc.2011.167
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrclinonc.2011.167

http://hdl.handle.net/1765/52329

Cite this

@article{c10d2dd40de54c55a53448798c4bbc41,

title = "MEDICAL ONCOLOGY Clinical value of circulating tumor cells in breast cancer",

abstract = "In a trial in patients with metastatic breast cancer, the prognostic value of the number of circulating tumor cells (CTCs) at baseline was independent of tumor subtype, except in patients with HER2-positive disease treated with anti-HER2 targeted therapy. These data support the use of CTC detection as a tool contributing to personalized medicine.",

author = "Stefan Sleijfer and John Foekens",

year = "2011",

doi = "10.1038/nrclinonc.2011.167",

language = "Undefined/Unknown",

volume = "8",

pages = "696--698",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - MEDICAL ONCOLOGY Clinical value of circulating tumor cells in breast cancer

AU - Sleijfer, Stefan

AU - Foekens, John

PY - 2011

Y1 - 2011

N2 - In a trial in patients with metastatic breast cancer, the prognostic value of the number of circulating tumor cells (CTCs) at baseline was independent of tumor subtype, except in patients with HER2-positive disease treated with anti-HER2 targeted therapy. These data support the use of CTC detection as a tool contributing to personalized medicine.

AB - In a trial in patients with metastatic breast cancer, the prognostic value of the number of circulating tumor cells (CTCs) at baseline was independent of tumor subtype, except in patients with HER2-positive disease treated with anti-HER2 targeted therapy. These data support the use of CTC detection as a tool contributing to personalized medicine.

U2 - 10.1038/nrclinonc.2011.167

DO - 10.1038/nrclinonc.2011.167

M3 - Article

SN - 1759-4774

VL - 8

SP - 696

EP - 698

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 12

ER -